The effect of statins on circulating endothelial progenitor cells in humans: A systematic review

Journal of Cardiovascular Pharmacology

Volumn 62, Issue 5, 2013, Pages 491-496

  Hibbert, Benjamin ^a   Simard, Trevor ^a   Ramirez, F Daniel ^a   Pourdjabbar, Ali ^a   Raizman, Joshua E ^a   Maze, Ronnen ^a   Wilson, Kumanan R ^b   Hawken, Steven ^b   O'Brien, Edward R ^c  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

endothelial progenitor cell; EPC; HMG CoA; statin; systematic review

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATORVASTATIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; ARTICLE; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG DOSE COMPARISON; DRUG EFFECT; ENDOTHELIAL PROGENITOR CELL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LOW DRUG DOSE; MORNING DOSAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STEM CELLS;

EID: 84888132478     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182a4027f     Document Type: Article

References (47)

1. Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999;84:413-428.
2. Pedersen TR. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
3. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995; 333:1301-1307.
4. Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin. 2003;19:540-556.
5. Hofnagel O, Luechtenborg B, Weissen-Plenz G, et al. Statins and foam cell formation: impact on LDL oxidation and uptake of oxidized lipoproteins via scavenger receptors. Biochim Biophys Acta. 2007;1771:1117-1124.
6. Halcox JPJ, Deanfield JE. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation. 2004;109:II42-II48.
7. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711-1718.
8. Vasa M, Fichtlscherer S, Adler K, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation. 2001;103:2885-2890.
9. Llevadot J, Murasawa S, Kureishi Y, et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest. 2001;108:399-405.
10. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964-967.
11. Dimmeler S, Aicher A, Vasa M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest. 2001;108:391-397.
12. Landmesser U, Engberding N, Bahlmann FH, et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation. 2004;110:1933-1939.
13. Hibbert B, Ma X, Pourdjabbar A, et al. Pre-procedural atorvastatin mobilizes endothelial progenitor cells: clues to the salutary effects of statins on healing of stented human arteries. PLoS One. 2011;6:e16413.
14. Hibbert B, Olsen S, O'Brien E. Involvement of progenitor cells in vascular repair. Trends Cardiovasc Med. 2003;13:322-326.
15. Hirschi KK, Ingram DA, Yoder MC. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol. 2008; 28:1584-1595.
16. Takahashi T, Kalka C, Masuda H, et al. Ischemia-and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 1999;5:434-438.
17. Ma X, Hibbert B, Dhaliwal B, et al. Delayed re-endothelialization with rapamycin-coated stents is rescued by the addition of a glycogen synthase kinase-3beta inhibitor. Cardiovasc Res. 2010;86:338-345.
18. Hibbert B, Ma X, Pourdjabbar A, et al. Inhibition of endothelial progenitor cell glycogen synthase kinase-3beta results in attenuated neointima formation and enhanced re-endothelialization after arterial injury. Cardiovasc Res. 2009;83:16-23.
19. Sata M, Saiura A, Kunisato A, et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med. 2002;8:403-409.
20. Hibbert B, Chen YX, O'Brien ER. c-kit-immunopositive vascular progenitor cells populate human coronary in-stent restenosis but not primary atherosclerotic lesions. Am J Physiol Heart Circ Physiol. 2004;287: H518-H524.
21. George J, Herz I, Goldstein E, et al. Number and Adhesive Properties of circulating endothelial progenitor cells in patients with in-stent restenosis. Arterioscler Thromb Vasc Biol. 2003;23:e57-e60.
22. Hill JM, Zalos G, Halcox JPJ, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003; 348:593-600.
23. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005;353:999-1007.
24. Yoshida O, Kondo T, Kureishi-Bando Y, et al. Pitavastatin, an HMGCoA reductase inhibitor, ameliorates endothelial function in chronic smokers. Circ J. 2010;74:195-202.
25. Spadaccio C, Pollari F, Casacalenda A, et al. Atorvastatin increases the number of endothelial progenitor cells after cardiac surgery: a randomized control study. J Cardiovasc Pharmacol. 2010;55:30-38.
26. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interverntions. 5th ed. West Sussex, England: The Cochrane Collaboration; 2008.
27. Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation. 2005;111:2356-2363.
28. Lu L, Zhou JZ, Wang L, et al. Effects of Xuezhikang and pravastatin on circulating endothelial progenitor cells in patients with essential hypertension. Chin J Integr Med. 2009;15:266-271.
29. Tousoulis D, Andreou I, Tsiatas M, et al. Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress. Atherosclerosis. 2011;214:151-157.
30. Leone AM, Rutella S, Giannico MB, et al. Effect of intensive vs standard statin therapy on endothelial progenitor cells and left ventricular function in patients with acute myocardial infarction: statins for regeneration after acute myocardial infarction and PCI (STRAP) trial. Int J Cardiol. 2008; 130:457-462.
31. Fadini GP, Losordo D, Dimmeler S. Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ Res. 2012;110:624-637.
32. Schmidt-Lucke C, Fichtlscherer S, Aicher A, et al. Quantification of circulating endothelial progenitor cells using the modified ISHAGE protocol. PLoS One. 2010;5:e13790.
33. Dimmeler S, Losordo D. Stem cells review series: an introduction. Circ Res. 2011;109:907-909.
34. Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation. 2002;105:3017-3024.
35. Assmus B, Urbich C, Aicher A, et al. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res. 2003;92: 1049-1055.
36. Pourdjabbar A, Hibbert B, Simard T, et al. Pathogenesis of neointima formation following vascular injury. Cardiovasc Hematol Disord Drug Targets. 2011;11:30-39.
37. Assmus B, Honold J, Schachinger V, et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med. 2006;355: 1222-1232.
38. Schachinger V, Erbs S, Elsañsser A, et al. Intracoronary bone marrowderived progenitor cells in acute myocardial infarction. N Engl J Med. 2006;355:1210-1221.
39. Hur J, Yoon CH, Kim HS, et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol. 2004;24:288-293.
40. Costiniuk CT, Hibbert BM, Simard T, et al. Circulating endothelial progenitor cells in HIV infection: a systematic review. Trends Cardiovasc Med. 2013;23:192-200.
41. Lin Y, Weisdorf DJ, Solovey A, et al. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest. 2000;105: 71-77.
42. Deschaseaux F, Selmani Z, Falcoz PE, et al. Two types of circulating endothelial progenitor cells in patients receiving long term therapy by HMG-CoA reductase inhibitors. Eur J Pharmacol. 2007;562: 111-118.
43. Baran Ç, Durdu S, Dalva K, et al. Effects of Preoperative Short Term Use of Atorvastatin on Endothelial Progenitor Cells after Coronary Surgery: A Randomized, Controlled Trial. Stem Cell Reviews and Reports 2012;8: 963-971.
44. Pirro M, Schillaci G, Romagno PF, et al. Influence of short-term rosuvastatin therapy on endothelial progenitor cells and endothelial function J Cardiovasc Pharmacol Therapeut 2009;14:14-21.
45. Yun KH, Shin I-S, Park EM, et al. Effect of additional statin therapy on endothelial function and prognosis in patients with vasospastic angina. Korean Circ J 2008;38:638-643.
46. Satoh M, Minami Y, Takahashi Y, et al. Effect of intensive lipidlowering therapy on telomere erosion in endothelial progenitor cells obtained from patients with coronary artery disease. Clin Sci 2009;116: 827-835.
47. Westerweel PE, Visseren FLJ, Hajer GR, et al. Endothelial progenitor cell levels in obese men with the metabolic syndrome and the effect of simvastatin monotherapy vs. simvastatin/ezetimibe combination therapy. Eur Heart J 2008;29:2808-2817.